enGene Holdings
ENGN
Market cap $203M

4.14 USD

+0.14

3.50%

At close Apr 30, 4:00 PM EDT

1 day

3.50%

5 days

3.76%

1 month

-7.59%

3 months

-41.69%

6 months

-52.30%

Year to date

-41.36%

1 year

-73.96%

5 years

-79.30%

10 years

-79.30%

About: enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Employees: 57

Healthcare Biotechnology

0

Funds holding %

of 7,425 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

43% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 7

21% more capital invested

Capital invested by funds: $228M [Q3] → $275M (+$47M) [Q4]

13% more funds holding

Funds holding: 30 [Q3] → 34 (+4) [Q4]

3.47% more ownership

Funds ownership: 77.55% [Q3] → 81.02% (+3.47%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

69%

upside

Avg. target

$22

431%

upside

High target

$34

721%

upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

0%

JMP Securities Silvan Tuerkcan 20% 1-year accuracy 10 / 51 met price target	335%upside $18	Market Outperform Reiterated	29 Apr 2025
Morgan Stanley Jeffrey Hung 16% 1-year accuracy 4 / 25 met price target	721%upside $34	Overweight Maintained	11 Mar 2025
HC Wainwright & Co. Andres Maldonado 28% 1-year accuracy 15 / 53 met price target	504%upside $25	Buy Reiterated	11 Mar 2025
Piper Sandler Allison Bratzel 55% 1-year accuracy 6 / 11 met price target	528%upside $26	Overweight Initiated	18 Feb 2025
UBS Colin Bristow 25% 1-year accuracy 3 / 12 met price target	69%upside $7	Neutral Downgraded	14 Feb 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about ENGN published over the past 30 days

enGene to Participate in Upcoming Investor Conferences

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that management will present at upcoming investor conferences in May 2025. Details of the conferences are below: Conference: 2025 Bloom Burton & Co. Healthcare Investor Conference Date: Monday, May 5, 2025 Time: 2:30 p.m. ET Format: Corporate Presentation Conference: The Citizens Life Sciences Conference Date: Wednesday,.

enGene to Participate in Upcoming Investor Conferences

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to seven newly-hired employees, with a grant date of April 2, 2025. The inducement awards consist of a non-qualified stock options to purchase an aggregate 144,650 of the Company's common shares. The options each have an exercise price of $4.44 per share, which is equal to the closing price.

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Stifel 2025 Virtual Targeted Oncology Forum, on Tuesday, April 8, 2025, at 4:00 p.m. ET. A live webcast of the presentation can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene e.

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2025, and provided a business update. “With the expansion of LEGEND study sites into Europe and Asia, enrollment in our pivotal cohort continues to track in-line with our plan to file a BLA for detalimogene in mid-2026,” said Ron Cooper, Chief Executive Officer o.

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

enGene to Participate in the Leerink Partners Global Healthcare Conference

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference, taking place in Miami, FL on Tuesday, March 11, 2025, at 1:00 p.m. ET. A live webcast of the fireside chat can be accessed under the “Investors” section of the enGene website at www.engene.com a.

enGene to Participate in the Leerink Partners Global Healthcare Conference

enGene Holdings Inc.: Unknown Company Which Looks Like A Catch

enGene's DDX platform delivers genetic cargo to mucosal tissues, showing potential to transform genetic medicine beyond rare diseases, with promising preclinical and clinical data. Detalimogene voraplasmid, enGene's lead asset, shows high complete response rates in BCG-unresponsive NMIBC patients, positioning it as a viable monotherapy option. Financials reveal a market cap of $320mn and a cash runway of 14–17 quarters, indicating undervaluation compared to market potential.

enGene Holdings Inc.: Unknown Company Which Looks Like A Catch

Zacks Investment Research

Best Momentum Stocks to Buy for February 19th

NVMI, FRSH and ENGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 19, 2024.

Best Momentum Stocks to Buy for February 19th

Zacks Investment Research

New Strong Buy Stocks for February 19th

GE, OPRT, ENGN, FRSH and NVMI have been added to the Zacks Rank #1 (Strong Buy) List on February 19, 2024.

New Strong Buy Stocks for February 19th

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today announced that Alex Nichols, Ph.D., Chief Strategy.

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today reported the grant of inducement equity awards to.

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

See News Rankings

Charts implemented using Lightweight Charts™